Perspective Therapeutics, Inc. (CATX)
3.105
0.00 (0.00%)
USD |
NYAM |
Sep 02, 16:00
3.105
0.00 (0.00%)
After-Hours: 19:41
Perspective Therapeutics Research and Development Expense (TTM) : 82.13M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 82.13M |
| March 31, 2026 | 77.61M |
| December 31, 2025 | 70.96M |
| September 30, 2025 | 61.22M |
| June 30, 2025 | 53.02M |
| March 31, 2025 | 46.41M |
| December 31, 2024 | 40.26M |
| September 30, 2024 | 33.44M |
| June 30, 2024 | 27.45M |
| March 31, 2024 | 21.48M |
| September 30, 2023 | 14.83M |
| June 30, 2023 | 10.02M |
| March 31, 2023 | 5.189M |
| June 30, 2022 | 2.582M |
| March 31, 2022 | 2.254M |
| December 31, 2021 | 2.067M |
| September 30, 2021 | 1.817M |
| June 30, 2021 | 1.427M |
| March 31, 2021 | 1.281M |
| December 31, 2020 | 1.213M |
| September 30, 2020 | 1.205M |
| June 30, 2020 | 1.126M |
| March 31, 2020 | 1.145M |
| December 31, 2019 | 1.15M |
| September 30, 2019 | 1.287M |
| Date | Value |
|---|---|
| June 30, 2019 | 1.474M |
| March 31, 2019 | 1.705M |
| December 31, 2018 | 1.879M |
| September 30, 2018 | 1.805M |
| June 30, 2018 | 1.747M |
| March 31, 2018 | 1.491M |
| December 31, 2017 | 1.345M |
| September 30, 2017 | 1.155M |
| June 30, 2017 | 0.965M |
| March 31, 2017 | 0.7917M |
| December 31, 2016 | 0.6479M |
| September 30, 2016 | 0.5561M |
| June 30, 2016 | 0.528M |
| March 31, 2016 | 0.5415M |
| December 31, 2015 | 0.4997M |
| September 30, 2015 | 0.5821M |
| June 30, 2015 | 0.6148M |
| March 31, 2015 | 0.6568M |
| December 31, 2014 | 0.669M |
| September 30, 2014 | 0.6984M |
| June 30, 2014 | 0.6688M |
| March 31, 2014 | 0.652M |
| December 31, 2013 | 0.6535M |
| September 30, 2013 | 0.6326M |
| June 30, 2013 | 0.6271M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Anika Therapeutics, Inc. | 27.45M |
| MiMedx Group, Inc. | 15.38M |
| ABVC BioPharma, Inc. | 0.1148M |
| Enovis Corp. | 124.32M |
| Edwards Lifesciences Corp. | 1.091B |